Equities analysts expect Qiagen NV (NASDAQ:QGEN) to announce $0.24 earnings per share (EPS) for the current quarter, according to Zacks. Three analysts have made estimates for Qiagen’s earnings. The lowest EPS estimate is $0.24 and the highest is $0.25. Qiagen posted earnings per share of $0.22 in the same quarter last year, which suggests a positive year-over-year growth rate of 9.1%. The firm is expected to issue its next earnings results after the market closes on Wednesday, May 2nd.
On average, analysts expect that Qiagen will report full year earnings of $1.34 per share for the current financial year, with EPS estimates ranging from $1.32 to $1.38. For the next year, analysts expect that the firm will report earnings of $1.53 per share, with EPS estimates ranging from $1.45 to $1.59. Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that follow Qiagen.
Qiagen (NASDAQ:QGEN) last posted its earnings results on Wednesday, January 31st. The company reported $0.43 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.42 by $0.01. The firm had revenue of $396.86 million for the quarter, compared to analyst estimates of $394.48 million. Qiagen had a return on equity of 11.74% and a net margin of 2.85%.
Several research firms have weighed in on QGEN. Morgan Stanley reduced their target price on Qiagen from $39.00 to $37.00 and set an “overweight” rating on the stock in a report on Wednesday, April 11th. Zacks Investment Research lowered Qiagen from a “hold” rating to a “sell” rating in a report on Monday, April 9th. DZ Bank reiterated a “neutral” rating on shares of Qiagen in a report on Thursday, April 5th. BidaskClub downgraded Qiagen from a “buy” rating to a “hold” rating in a research note on Thursday, March 15th. Finally, TheStreet downgraded Qiagen from a “b-” rating to a “c+” rating in a research note on Thursday, February 8th. One analyst has rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $35.11.
QGEN stock opened at $32.81 on Friday. The company has a current ratio of 5.07, a quick ratio of 4.59 and a debt-to-equity ratio of 0.69. Qiagen has a 1-year low of $28.65 and a 1-year high of $36.34.
Qiagen announced that its board has initiated a stock buyback plan on Wednesday, January 31st that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. American International Group Inc. acquired a new stake in shares of Qiagen in the 4th quarter valued at about $154,000. Lourd Capital LLC acquired a new stake in shares of Qiagen in the fourth quarter valued at about $223,000. Bronfman E.L. Rothschild L.P. increased its position in shares of Qiagen by 50.8% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 11,451 shares of the company’s stock valued at $354,000 after acquiring an additional 3,860 shares during the last quarter. State of Alaska Department of Revenue acquired a new stake in shares of Qiagen in the fourth quarter valued at about $445,000. Finally, Nisa Investment Advisors LLC increased its position in shares of Qiagen by 65.9% in the fourth quarter. Nisa Investment Advisors LLC now owns 21,401 shares of the company’s stock valued at $662,000 after acquiring an additional 8,500 shares during the last quarter. 62.23% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Zacks: Brokerages Expect Qiagen NV (QGEN) to Post $0.24 EPS” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/23/zacks-brokerages-expect-qiagen-nv-qgen-to-post-0-24-eps.html.
Qiagen Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Get a free copy of the Zacks research report on Qiagen (QGEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.